Aromics, CataloniaBio & HealthTech member, has been awarded with 1,085.659 euros from the European Union for the regulatory preclinics of NAX035 for the treatment of malignant mesothelioma, an aggressive and highly refractory tumor directly related to asbestos exposure.
The financing of Aromics comes through the SME instrument Phase 2 of the Horizon 2020 program, which allows European companies to develop innovative products and services.
The use of asbestos will be definitively banned in the European Union in 2005 but it is a tumour with a long latency period (30 to 40 years from the exposure to the diagnosis), for which a high increase in its incidence in Europe is expected from 2020. The European Economic and Social Committee estimates that more than 300,000 Europeans will die per mesothelioma by 2030.
Aromics has its headquarters and lab at the Barcelona Science Park.
Photo: Carme Plasencia, founder and CEO of Aromics - © Aromics
Comments